Top Markets
Coin of the day
Hugel, Inc. Hugel, Inc.

Hugel, Inc.

145020
株式のランク #6786
Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South... Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.
株価
$173.56
時価総額
$1.88B
変化(1日)
2.24%
変化(1年)
-24.15%
KR
取引 Hugel, Inc. (145020)

カテゴリー

Hugel, Inc.(145020)の配当利回りの履歴
Hugel, Inc.(銘柄コード: 145020)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Hugel, Inc.(145020)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)